Diamyd Medical AB, a Swedish diabetes company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications, announced it plans to file the Diamyd® diabetes vaccine for market approval in 2011.
The European Phase III study with Diamyd® has been fully recruited meaning that the first results from the study can be reported during spring 2011. A recruitment campaign for the US study has been launched together with the recruitment firm Inclinix under the name DiaPrevent, and the number of patients recruited for the study is increasing at a fast pace.
Albert,
I think you will find the answer here at Diamyd´s website.
http://www.diamyd.com/
Shortly, the Diamyd vaccin seems to stop the immune attack which is killing the beta cells.
How could Diamyd Medical produce a vaccine to prevent and treat type 1 diabetes when no one knows what causes type 1 diabetes in the first place.